ACCUMULATED LABORATORY DATA IN B12 VITAMIN BLOOD LEVEL TIME DEPENDENCY STUDIES IN PATIENTS WITH MYELOMA, LYMPHOCYTIC LEUKEMIA AND MYELOBLASTIC LEUKEMIA IN LATVIA

Authors

  • Didzis Gavars Egils Gulbis Laboratory, Riga Stradiņš University (LV)
  • Agris Auce University of Latvia (LV)
  • Ēriks Tauckels Egils Gulbis Laboratory (LV)
  • Agnese Miķelsone Riga Stradiņš University (LV)
  • Anna Inese Tutane Egils Gulbis Laboratory, Riga Stradiņš University (LV)

DOI:

https://doi.org/10.17770/etr2023vol2.7220

Keywords:

B12 vitamin, myeloma, lymphocytic leukemia, myeloblastic leukemia, laboratory data

Abstract

Vitamin B12 blood level in patients with myeloma (C90 - International Classification of Diseases (ICD-10)), lymphocytic leukemia (C91) and myeloblastic leukemia (C92) prior and after the diagnosis and also BCR-ABL (fusion gene from breakpoint cluster region BCR gene and tyrosine-protein kinase ABL1 (Abelson murine leukemia) gene) tests for C92 patients were studied.

Clinical records of 20 C92 patients in Riga East University Hospital were complemented with 6987 B12 clinical test data accumulated in E Gulbis laboratory (EGL) for 7451 patients over 20 years period. BCR-ABL and B12 dynamics for 11 patients with sufficient number of BCRABL and B12 tests were studied.

Oracle Cloud with pseudonymized data replica from more than 350 000 000 original EGL clinical test data was used. The data were selected by online analytical processing and SQL built in tools and then used in offline analysis and visualization.

Annually there are 107, 189 and 91 confirmed cases of C90, C91 and C92 in Latvia. EGL has 30% more C90-92 patients, due to suspected but later unconfirmed cases. Out of 7451 patients 1386 had one B12 test, two- 548, three and more- 864. The patients with diagnosis fluctuating between C90, C91 and C92 were excluded from the study. The data for the time period of 10 years before and after the first diagnosis were analyzed.

Results. Methods and tools for data extraction and analysis from large amount of archived clinical test data were developed and applied. High and very high B12 level was observed for 53% of C92 patients starting from 3 years prior to diagnosis. For C90 and C91 patients B12 level changes around the diagnosis date were also observed although the effect was considerably smaller. Analysis of 11 selected patient data with clinical records showed timewise correlation between B12 and BCR-ABL for 3 of the patients.

 

Downloads

Download data is not yet available.

References

Y. Ozarda, K. Ichihara, G. Jones, T. Streichert, and R. Ahmadian, “Comparison of reference intervals derived by direct and indirect methods based on compatible datasets obtained in Turkey,” Clinica Chimica Acta, vol. 520, pp. 186–195, Sep. 2021, doi: 10.1016/j.cca.2021.05.030.

World Health Organization, “International statistical classification of diseases and related health problems, 10th revision, Fifth edition,” 2016. [Online]. Available: https://apps.who.int/iris/handle/10665/246208 /. [Accessed March 24, 2023]

“Latvian Health Statistics Database.” [Online]. Available: https://statistika.spkc.gov.lv/pxweb/lv/Health/ [Accessed March 24, 2023]

P. A. Thompson, H. M. Kantarjian, and J. E. Cortes, “Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015,” Mayo Clin. Proc., vol. 90, no. 10, pp. 1440–1454, 2015. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.1016/j.mayocp.2015.08.010

S. Federl, M. Talpaz, Z. Estrov, S. O’Brien, R. Kurzrock, and H. M. Kantarjian, “The Biology of Chronic Myeloid Leukemia,” N. Engl. J. Med., 1999. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.1056/NEJM199907153410306

I. Ādamsone et al., Klīniskā Medicīna. Pirmā grāmata. SIA Medicīnas apgāds Rīgā, 2010.

D. Seong et al., “Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization,” 1999. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.1023/a:1008349405763

F. Onida et al., “Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia,” Cancer, vol. 95, no. 8, pp. 1673–1684, 2002. Available, Acs Journals, https://acsjournals.onlinelibrary.wiley.com/ [Accessed March 24, 2023] https://doi.org/10.1002/cncr.10832

P. Martiat, J. L. Michaux, and J. Rodhain, “Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): Comparison with Ph+ CML and chronic myelomonocytic leukemia,” Blood, vol. 78, no. 1, pp. 205–211, 1991.

H. M. Kantarjian et al., “Clinical and prognostic features of philadelphia chromosome-negative chronic myelogenous leukemia,” Cancer, vol. 58, no. 9, pp. 2023–2030, Nov. 1986.

Cepheid, “Manual: The Xpert BCR-ABL Ultra by Cepheid GeneXpert Instrument Systems,” 2018.

D. Gavars, D. Perminov, E. Tauckels, I. Lindenberga, A. Auce, and S. Lejniece, “Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia,” Exp. Oncol., vol. 41, no. 4, pp. 357–362, 2019 Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.32471/exp-oncology.2312-8852.vol-41-no-4.13930

E. Fischer, “Studies on the abnormal high binding capacity of blood for vitamin B12 in chronic myeloid leukemia,” Clin. Chim. Acta, 36 (1972) 409-418 Available, Science Direct https://www.sciencedirect.com/. [Accessed March 24, 2023] https://doi.org/10.1016/0009-8981(72)90016-2

J. F. B. Arendt, L. Pedersen, E. Nexo, and H. T. Sørensen, “Elevated plasma vitamin B12 levels as a marker for cancer: A population-based cohort study,” J. Natl. Cancer Inst., vol. 105, no. 23, pp. 1799–1805, 2013. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.1093/jnci/djt315

J. F. B. Arendt and E. Nexo, “Cobalamin Related Parameters and Disease Patterns in Patients with Increased Serum Cobalamin Levels,” PLoS One, vol. 7, no. 9, 2012. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] doi: 10.1371/journal.pone.0045979

E. Andrès, K. Serraj, J. Zhu, and A. J. M. Vermorken, “The pathophysiology of elevated vitamin b12 in clinical practice,” Qjm, vol. 106, no. 6, pp. 505–515, 2013. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.1093/qjmed/hct051

R. Obeid, “High Plasma Vitamin B12 and Cancer in Human Studies: A Scoping Review to Judge Causality and Alternative Explanations,” Nutrients, vol. 14, no. 21, 2022. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.3390/nu14214476

J. F. B. Arendt and E. Nexo, “Unexpected high plasma cobalamin,” Clin. Chem. Lab. Med., vol. 51, no. 3, pp. 489–496, 2013. Available, Pub Med https://pubmed.ncbi.nlm.nih.gov/. [Accessed March 24, 2023] DOI: 10.1515/cclm-2012-0545

Referenzinstitut für Bioanalytik. (2020). Vitamin B12 external quality con-trol dataset April 2020. https://www.rfb.bio/ [Accessed April 20, 2023]

Downloads

Published

2023-06-13

Issue

Vol. 2 (2023): Environment. Technology. Resources. Proceedings of the 14th International Scientific and Practical Conference. Volume 2

Section

Information Technologies

How to Cite

[1]
D. Gavars, A. Auce, Ēriks Tauckels, A. Miķelsone, and A. I. Tutane, “ACCUMULATED LABORATORY DATA IN B12 VITAMIN BLOOD LEVEL TIME DEPENDENCY STUDIES IN PATIENTS WITH MYELOMA, LYMPHOCYTIC LEUKEMIA AND MYELOBLASTIC LEUKEMIA IN LATVIA”, ETR, vol. 2, pp. 34–39, Jun. 2023, doi: 10.17770/etr2023vol2.7220.